Cargando…
Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
Chronic myelogenous leukemia (cml) is a disease characterized by the expression of Bcr/Abl, an oncogenic protein tyrosine kinase, and by evolution over time from a relatively benign chronic phase to a rapidly fatal cml blast crisis. Until recently, the standard of care included potentially curative...
Autores principales: | Laneuville, P., Barnett, M.J., Bélanger, R., Couban, S., Forrest, D.L., Roy, D.C., Lipton, J.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394607/ https://www.ncbi.nlm.nih.gov/pubmed/22792021 |
Ejemplares similares
-
An approach to the management of chronic myeloid leukemia in British Columbia
por: Forrest, D.L., et al.
Publicado: (2008) -
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018) -
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations
por: Chinsky, Jeffrey M, et al.
Publicado: (2017) -
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021) -
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)